Tyler Van Buren
Stock Analyst at TD Cowen
(1.60)
# 3,208
Out of 4,869 analysts
57
Total ratings
39.13%
Success rate
-6.02%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $25.55 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $13.49 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $14.46 | +418.67% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $9.32 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $11.69 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $25.90 | +131.66% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $1.58 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $9.76 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $509.72 | +135.42% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $19.79 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $17.96 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $108.50 | -21.66% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $44.25 | -32.20% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.27 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.01 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $63.00 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.96 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $14.33 | +109.35% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.73 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.19 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $31.34 | +123.36% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.30 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.44 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.23 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.73 | +2,790.17% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $15.00 | +1,400.00% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $7.55 | +11,489.40% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $3.99 | +902.51% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $11.48 | +248.43% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $10.65 | +181.69% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.38 | +15,815.12% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.28 | +3,806.25% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.44 | +1,983.33% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $2.24 | +8,828.57% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.21 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.95 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $25.55
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $13.49
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $14.46
Upside: +418.67%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $9.32
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $11.69
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $25.90
Upside: +131.66%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $1.58
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $9.76
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $509.72
Upside: +135.42%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $19.79
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $17.96
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $108.50
Upside: -21.66%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $44.25
Upside: -32.20%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.27
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.01
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $63.00
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $41.96
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $14.33
Upside: +109.35%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $41.73
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.19
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $31.34
Upside: +123.36%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.30
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.44
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.23
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.73
Upside: +2,790.17%
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $15.00
Upside: +1,400.00%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $7.55
Upside: +11,489.40%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $3.99
Upside: +902.51%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $11.48
Upside: +248.43%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $10.65
Upside: +181.69%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.38
Upside: +15,815.12%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.28
Upside: +3,806.25%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.44
Upside: +1,983.33%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $2.24
Upside: +8,828.57%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $3.21
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.95
Upside: -